


Supplementary Figure S11



Supplementary Figure S11. Direct treatment of TAM with PI3Ki + MEKi + PORCNI therapy

does not alter TAM phagocytic capacity. (A) Experimental schema: Direct treatment of FACS-sorted TAM subsets (MHC-II<sup>hi/lo</sup>/PD-1<sup>hi/lo</sup>) from PTEN/p53-deficient prostate tumors with copanlisib (C, 100 nM), trametinib (T, 5 nM), LGK'974 (L, 50 nM) or their combination for 24 hours. Following treatment, TAM were co-cultured with CTV dye stained-AC1/SC1 cells for 2

hours. Bar graphs demonstrate (B) histone lactylation status and (C) phagocytic activity of PD-1<sup>hi/lo</sup>MHC-II<sup>hi/lo</sup> expressing TAM relative to untreated group. FC = fold change. n=2 independent biological experiments. Significances/p-values were calculated by one-way ANOVA.